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Abstract
Background: Organised colorectal cancer screening is likely to be cost-effective, but cost-effectiveness results alone
may not help policy makers to make decisions about programme feasibility or service providers to plan programme
delivery. For these purposes, estimates of the impact on the health services of actually introducing screening in the
target population would be helpful. However, these types of analyses are rarely reported. As an illustration of such
an approach, we estimated annual health service resource requirements and health outcomes over the first decade
of a population-based colorectal cancer screening programme in Ireland.
Methods: A Markov state-transition model of colorectal neoplasia natural history was used. Three core screening
scenarios were considered: (a) flexible sigmoidoscopy (FSIG) once at age 60, (b) biennial guaiac-based faecal occult
blood tests (gFOBT) at 55–74 years, and (c) biennial faecal immunochemical tests (FIT) at 55–74 years. Three
alternative FIT roll-out scenarios were also investigated relating to age-restricted screening (55–64 years) and
staggered age-based roll-out across the 55–74 age group. Parameter estimates were derived from literature review,
existing screening programmes, and expert opinion. Results were expressed in relation to the 2008 population
(4.4 million people, of whom 700,800 were aged 55–74).
Results: FIT-based screening would deliver the greatest health benefits, averting 164 colorectal cancer cases and
272 deaths in year 10 of the programme. Capacity would be required for 11,095-14,820 diagnostic and surveillance
colonoscopies annually, compared to 381–1,053 with FSIG-based, and 967–1,300 with gFOBT-based, screening. With
FIT, in year 10, these colonoscopies would result in 62 hospital admissions for abdominal bleeding, 27 bowel
perforations and one death. Resource requirements for pathology, diagnostic radiology, radiotherapy and colorectal
resection were highest for FIT. Estimates depended on screening uptake. Alternative FIT roll-out scenarios had lower
resource requirements.
Conclusions: While FIT-based screening would quite quickly generate attractive health outcomes, it has heavy
resource requirements. These could impact on the feasibility of a programme based on this screening modality.
Staggered age-based roll-out would allow time to increase endoscopy capacity to meet programme requirements.
Resource modelling of this type complements conventional cost-effectiveness analyses and can help inform policy
making and service planning.
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Background
Various international organisations have recommended
screening for colorectal cancer [1,2]. While screening
programmes are in place, or being piloted, in several
European countries [3], many other countries have not
yet implemented screening. Several screening tests are
available. These include endoscopy-based tests (such as col-
onoscopy and flexible sigmoidoscopy (FSIG)), radiology-
based tests (such as barium enema and CT colonography)
and faecal tests (such as the guaiac-based faecal occult
blood (gFOBT) and faecal immunochemical test (FIT)).
Each test has its own strengths and limitations [4]. In
addition, while most cost-effectiveness analyses suggest that
organised screening - by most of the available tests - is
likely to be considered cost-effective, none of the tests ap-
pears optimal across all settings [5]. This creates consider-
able uncertainty for those tasked with making policy and
providing services.
Cost-effectiveness is only one of the issues which
needs to be considered when taking decisions on screen-
ing implementation. Long-established criteria from the
World Health Organisation (WHO) recommend also
considering the safety of the screening test and associ-
ated diagnostic investigations, the acceptability of the
test, and availability of diagnosis and treatment facilities
[6]. The challenge for policy-makers is, therefore, how to
take all of these issues into account in weighing screen-
ing options against one another to determine the “best”
strategy in a given setting. The challenge for health ser-
vice planners is slightly different: it concerns how to de-
liver the screening tests and associated health services
required for diagnosis, treatment and follow-up. Both of
these challenges are further complicated by demographic
changes in western populations, which mean that the
population in the screening age-range is projected to
rise. Moreover, screening tests which are repeated regu-
larly (e.g. faecal tests) impact on the eligible population,
since people diagnosed with cancer or adenoma(s) are
no longer eligible to be invited for screening. Thus con-
sideration needs to be given to capacity requirements
immediately upon programme implementation and over
the coming five, ten or twenty years. Cost-effectiveness
analyses, with results expressed in costs per quality ad-
justed life year gained (QALY) or life years saved (LYS),
may not help health service managers address such prac-
tical issues [7]. Other types of analyses, which express
the real, immediate, impact on the health services of actu-
ally introducing a screening programme (such as budget
impact [8] or other similar analyses) may be of more use.
However, these other types of analyses are rarely reported.
We conducted a cost-effectiveness analysis of three
strategies for colorectal cancer screening in Ireland:
biennial gFOBT at ages 55–74, biennial FIT at ages 55–74
and once-only FSIG at age 60. All three options were
considered to be highly cost-effective compared to the sta-
tus quo of no screening. The cost per QALY gained was
€589 for FSIG, €1,696 for FIT and €4,428 for gFOBT [9].
FIT-based screening was expected to result in the greatest
gain in QALYs and largest reductions in cancer incidence
and mortality once fully implemented (i.e. the population
cohort had completed 10 screening rounds). However, it
was associated with major resource requirements over the
lifetime of the cohort and higher rates of screening-related
harms, including bowel perforations and deaths, than the
other options. These results presented a significant chal-
lenge for decision-makers and service providers, raising
questions about the feasibility, practicality and acceptabil-
ity of a programme based on screening individuals aged
55–74 by biennial FIT. For example, there were questions
about the actual resources required for diagnosis and
treatment (for example, the numbers of colonoscopies
which would need to be conducted), whether the service
could deliver these, and the impact of higher than esti-
mated uptake. Safety was also a concern, with questions
about the actual number of people expected to suffer ad-
verse effects of screening each year, and whether this was
likely to be within acceptable limits. These questions stim-
ulated queries about whether taking a different approach
to screening delivery would make a programme based on
FIT more feasible: for example, initially offering screening
to a restricted age-group with gradual roll-out to incorp-
orate the full age-range (as has been done in England in
relation to the roll-out of the gFOBT-based screening
programme). These types of questions cannot be an-
swered by a conventional cost-effectiveness analysis.
In this paper we describe how we used a Markov state-
transition model to estimate health service resource re-
quirements and health outcomes, relative to the actual
population of Ireland, over the first decade of a population-
based colorectal cancer screening programme. These ana-
lyses were done with a view to aiding decision-making and
service planning, and intended to complement the cost-
effectiveness analyses.
Methods
Setting and screening scenarios
The country of Ireland is a republic comprising the lar-
gest part of the island of Ireland (the remainder of the
island is Northern Ireland). The country has a popula-
tion of 4.4 million, 700,800 of whom are aged 55–74.
The healthcare system involves a mixture of public and
private provision. Cancer screening programmes are
provided free at the point of delivery, so the costs of
provision fall on the healthcare payer, in this instance
the Health Service Executive (HSE).
This analysis was part of a health technology assess-
ment (HTA) of population-based colorectal cancer
screening in Ireland. The commissioners, the Health
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Information & Quality Authority, established an Expert
Group to scope the HTA, and recommend which screen-
ing modalities and age-groups should be evaluated [10].
These decisions were informed by: the available scientific
evidence at the time, age-specific colorectal cancer inci-
dence and mortality in Ireland, and considerations of feasi-
bility and likely acceptability. The three base-case scenarios
recommended for evaluation were: (1) biennial gFOBT,
with reflex FIT (i.e. those with a weak positive gFOBT
would be invited to complete a FIT), in individuals aged
55–74 years; (2) biennial FIT in individuals aged 55–74
years; and (3) once-only FSIG at age 60. Investigation of
positive screening tests was assumed to be by colonoscopy
or, in those unfit for colonoscopy, by CT colonography.
Follow-up of those who had adenomas detected and re-
moved was assumed to follow existing guidelines [11]. For
gFOBT and FIT, we assumed that approximately half the
population aged 55 or 56 would be invited to participate in
year one of the programme and the remainder in year two,
and similarly for those aged 57 or 58, and so on. Thus
biennial screening in the 55–74 age group involved a max-
imum of ten screening rounds.
Since FIT-based screening was considered the optimal
option in terms of cost-effectiveness, health service re-
quirements associated with alternative scenarios for
implementing FIT-screening were also considered. The
two main alternative implementation approaches involve
either restrictions by area or by age. The former is con-
sidered unacceptable by the National Cancer Screening
Service (NCSS) in Ireland, so only age-based implemen-
tation strategies were considered. The first variant in-
volved restricting screening to the 55–64 age-group (i.e.
a maximum of five screening rounds). The second and
third variants involved staggered roll-out of biennial
screening in the 55–74 age-group. “Medium implemen-
tation” involved inviting those aged 55 and 65 in year
one; those aged 55, 57, 65 and 67 in year two; those aged
55, 57, 59, 65, 67 and 69 in year three; and so on until
the full age range would be included in year five. “Slow
implementation” involved inviting those aged 55 in year
one; those aged 55 and 57 in year two, those aged 55, 57
and 59 in year three; and so on until year ten when the
full age-range would be included. These scenarios were
not intended to represent the only or preferred options,
but rather were chosen to illustrate the health service im-
pact of different possible approaches to implementation.
Estimating resource use and health outcomes
“Conventional” analysis of a Markov model - for the
purposes of cost-effectiveness analysis - follows a single
notional cohort, usually comprising 100,000 individuals,
over their lifetime accumulating costs and benefits as
the cohort ages. The approach adopted for this analysis
was similar to that taken in a budget impact analysis [8].
We considered a short time horizon - the first 10 years
following screening implementation. We estimated re-
quirements separately for a range of resources (from
screening tests to colorectal resections). We expressed
our results in relation to the actual target population in
Ireland. To do this, we ran our economic model, de-
scribed below, using a cross-sectional whole population
approach. We established 70 different age-cohorts, cor-
responding to the 2008 Irish population; cohort one
comprised individuals aged 30, cohort two comprised in-
dividuals aged 31, and so on. We followed these 70 age-
cohorts through the model for 10 years. For each cohort,
the screening-related resources required (e.g. screening
tests, diagnostic tests, etc.) and health outcomes experi-
enced (e.g. numbers diagnosed with adenomas, had bowel
perforations) were estimated, then summed across the
whole population (i.e. all 70 cohorts) for each year follow-
ing screening implementation. The predictions incorpo-
rated changes in the population age distribution over time
and lower cancer prevalence in later screening rounds.
Resources associated with screening were assumed to
be provided by the HSE and, within that, the NCSS.
The health service resources estimated included those
associated with: screening (gFOBT and FIT kits dis-
patched and returned; FSIG examinations); and diagno-
sis and treatment of screen-detected lesions (up to and
including the point of surgery) and surveillance of indi-
viduals with screen-detected adenomas (colonoscopy,
CT colonography, pathology, diagnostic radiology, neo-
adjuvant radiotherapy (with or without chemotherapy)
and colorectal resection). The health outcomes consid-
ered were the numbers of individuals who were diag-
nosed with screen-detected adenomas and cancers and
the numbers who sustained complications (major ab-
dominal bleeding requiring hospital admission, bowel
perforation, death following perforation).
Model
We used a Markov state-transition model which is de-
scribed in detail elsewhere [9,12]. Briefly, the model in-
cluded three interlinked components relating to: (a) the
natural history of colorectal neoplasia; (b) screening sce-
narios, and subsequent adenoma surveillance; and (c)
mortality. The natural history model simulated the experi-
ence of a cohort of individuals over their lifetime (from
age 30 to 100) through a finite number of defined health
states relating to the progression from having normal
colorectal epithelium though the adenoma-carcinoma se-
quence to death (Additional file 1: Figure S1). The screen-
ing intervention model was superimposed upon the
natural history model and the impact of the screening and
diagnostic tests, and management of adenomas and can-
cers, modelled by re-distributing the cohort across health
states in each Markov cycle. The mortality model allowed
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for deaths due to colorectal cancer, endoscopic bowel per-
foration, and other causes.
Parameters and calibration
To populate the model, comprehensive literature reviews
were undertaken. These were augmented with data and
results from population-based screening programmes
and pilot programmes. When relevant data was unavail-
able, values were based on expert clinical opinion.
Table 1 shows the parameter values and the sources
from which they were derived [13-49].
Base-case estimates of screening uptake and colonos-
copy compliance came from the UK pilot colorectal can-
cer screening programmes and the UK FSIG trial
[34,35,38]. GFOBT and FIT uptake were assumed to be
the same and not to change over screening rounds.
Compliance with post-polypectomy surveillance was as-
sumed to be the same as with diagnostic colonoscopy.
GFOBT and FIT sensitivity and specificity values were
derived from pooled analysis of information from diag-
nostic cohort studies of “screening populations” (i.e. the
diagnosis had not been determined prior to recruitment
and all participants underwent the index test and the
reference “gold-standard” test) and, for gFOBT, which
used HemoccultW or Hemoccult IIW [13-32]. While we
did not set out to evaluate FIT at different cut-off values
(because of lack of high-quality data at the time the
model was parameterized) the key studies which in-
formed the parameter estimates for FIT performance
characteristics used a cut-off of 100 ng/mL. Three stud-
ies were combined to estimate FSIG sensitivity for inter-
mediate/high-risk adenomas (adenomas ≥10 mm in size)
[18,20,33]. Estimates of sensitivity for low-risk adenomas
(<10 mm) and cancers, and specificity, were based on
expert clinical opinion; these estimates were based on
the assumption that sensitivity for low-risk adenomas
would be lower than that for high-risk adenomas and
sensitivity for cancer would be higher than that for high-
risk adenomas. Colonoscopy performance characteristics
were based on “miss rates” from studies of individuals
who had undergone tandem colonoscopies [41,42]. CT
colonography performance characteristics were based on
expert opinion informed by reviews and large-scale stud-
ies [43-46]. It was assumed that, on average, 1.9 aden-
omas would be removed from each person undergoing
polypectomy [47]. The probability of perforation follow-
ing FSIG was derived from the UK FSIG Trial [38]. For
colonoscopy, probabilities of perforation (with and with-
out polypectomy) were estimated from a Swedish na-
tionwide colonoscopy audit [49]. Estimates of the
probability of death following perforation came from
Gatto et al. [48]. Estimates of major bleeding following en-
doscopy procedures were from the UK FSIG Trial [38].
Several parameters, including natural history transition
probabilities, could not be empirically observed and
were obtained by calibration: This involved fitting the
model to colorectal cancer incidence (by stage) and mor-
tality data for Ireland. Further details of the approach
and the transition probabilities are provided elsewhere
[9,50]. The colorectal cancer incidence and mortality
figures predicted by the model were very close to the ob-
served values [9].
Analysis
The primary analysis concerned absolute screening im-
pact (i.e. annual numbers of each health service resource
required, and each health outcome, under each screen-
ing scenario). One-way sensitivity analyses explored the
impact of varying (a) screening uptake, (b) screening test
sensitivity and (c) screening test specificity. Values for
lower and higher uptake were based on experience in
other countries [36,37,39,40]. For test sensitivity and
specificity, the values used were the lower and upper
95% confidence intervals obtained from the pooled data
used to derive the base-case values.
The secondary analysis assessed the relative impact of
screening. For each core screening scenario, we esti-
mated the additional resources needed for diagnosis and
treatment, and the population-level health gains, com-
pared to those required or generated under a policy of
no screening.
Results
Primary (absolute) analysis of base-case scenarios
The model predicted that, in year one of a programme
based on gFOBT or FIT, 357,812 individuals would be
sent test kits, and 189,640 completed kits would be
returned for laboratory processing (Table 2). With a
FSIG-based programme, in year one, an estimated
18,617 individuals would undergo screening. Assuming
uptake remained constant, between years one and 10,
the number screened by FIT or gFOBT would increase
by 16-17% and by FSIG by 11%, due to demographic
changes.
For FIT-based screening, in year one, resources would
be required to perform 11,095 diagnostic colonoscopies
and 1,441 CT colonographies, rising to 12,414 colonos-
copies and 1,614 CT colonographies in year 10. The
diagnostic resources required under gFOBT screening
would be one-tenth of those required for FIT. With
once-only FSIG, only 381–423 individuals would
undergo diagnostic colonoscopy each year. Similar pat-
terns were evident in the colonoscopy and CT
colonography resources required for surveillance of
those with intermediate/high-risk adenomas removed.
As a consequence of the numbers of colonoscopies,
more individuals would suffer adverse events with
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screening based on FIT, than with screening based on
gFOBT or FSIG. With FIT, in year 10, an estimated 62
people would suffer major abdominal bleeding resulting
in hospital admission, and there would be 27 bowel per-
forations and one associated death.
The yield of adenomas and cancers was predicted to
be higher for FIT-based screening than the other two
options, and therefore the resources required to manage
these would be much greater. In year one, under FIT-
based screening, 7,161 lesions (6,308 adenomas and 853
Table 1 Parameter estimates
Model parameter Base-case value Lower and upper values in
sensitivity analysis
References
Performance of screening tests
gFOBT sensitivity for adenomas 11% 10%, 12%1 [13-21]
gFOBT sensitivity for CRC 36% 31%, 42%1
gFOBT specificity for adenomas and CRC 97% 96%, 98%
FIT sensitivity for adenomas 21% 19%, 22%1 [16,22-32]
FIT sensitivity for CRC 71% 67%, 75%1
FIT specificity for adenomas and CRC 95% 94%, 96%
FSIG sensitivity for low-risk distal adenomas 65% 60%, 70%1 Expert opinion informed by [18,20,22]
FSIG sensitivity for intermediate/high-risk distal adenomas 74% 68%, 78%1
FSIG sensitivity for distal CRC 90% 85%, 95%1
FSIG specificity for distal adenomas and CRC 92% 90%, 95%
Uptake and compliance with screening, diagnosis and surveillance
gFOBT uptake 53% 32%, 70% [34-37]
FIT uptake 53% 32%, 70%
FSIG uptake 39% 24%, 67% [38-40]
COL compliance (diagnostic test or adenoma surveillance) 86% - [34,35]
Performance of diagnostic tests and related parameters
COL sensitivity for low-risk adenomas 77% - [41,42]
COL sensitivity for intermediate/high-risk adenomas 98% -
COL sensitivity for CRC 98% -
COL specificity for adenomas and CRC 97% - Expert opinion
CTC sensitivity for low-risk adenomas 53% - Expert opinion, informed
by [43-46]
CTC sensitivity for intermediate/high-risk adenomas 85% -
CTC sensitivity for CRC 85% -
CTC specificity for adenomas and CRC 86% -
Average number of adenomas removed per person 1.9 - [47]
% of those with intermediate/high-risk adenomas removed
in whom the adenoma was high-risk
29% - [34]
Harms of screening
FSIG probability of perforation (with or without polypectomy) 0.002% - [38]
FSIG probability of death following perforation 6.452% - [48]
Probability of (major) bleeding following FSIG 0.029% - [38]
COL probability of perforation (with polypectomy) 0.216% - [49]
COL probability of perforation (without polypectomy) 0.107% -
COL probability of death following perforation 5.195% - [48]
Probability of (major) bleeding following COL 0.379% - [38]
COL colonoscopy, CRC colorectal cancer, CTC CT colonography, FIT faecal immunochemical test, gFOBT guaiac faecal occult blood test, FSIG flexible sigmoidoscopy;
low-risk adenoma(s), <10 mm; intermediate/high-risk adenoma(s), ≥10 mm. 1 parameters varied simultaneously in sensitivity analysis; - parameters not varied in
sensitivity analyses.
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cancers) would require pathological analysis, compared
to 1,599 (1,525 and 64) using FSIG, and 1,004 (695 and
309) using gFOBT. Resources would be required to con-
duct 774 resections of screen-detected cancers in year
one with FIT screening, compared to 280 with gFOBT
and 59 with FSIG. In year 10, these numbers would rise
to 635, 307 and 71 for FIT, gFOBT and FSIG screening,
respectively.
Sensitivity analyses
Numbers of diagnostic colonoscopies and screen-detected
cancers estimated from the sensitivity analyses are shown
in Additional file 2: Table S1 for all three screening scenar-
ios, and in Figure 1 for biennial FIT at 55–74 years. Vary-
ing screening uptake had the greatest impact. For
example, for FIT-based screening, compared to base-case
uptake (53%), with low uptake (32%) the annual number
Table 2 Estimated screening-related resource use and health outcomes by year and screening scenario: biennial gFOBT
at 55–74 years, biennial FIT at 55–74 years, and FSIG once at 60 years
Year of programme Year 1 Year 10
Screening scenario gFOBT FIT FSIG gFOBT FIT FSIG
Screening-related resource use
Screening tests No. of kits sent out 357,812 357,812 420,151 417,464
No. of kits processed 189,640 189,640 222,637 220,999
No. of FSIG done1 18,617 20,625
COL/CTC No. of diagnostic COL 967 11,095 381 1,103 12,414 423
No. of diagnostic CTC 126 1,442 50 143 1,614 55
No. of surveillance COL 0 0 0 297 2,406 620
No. of surveillance CTC 0 0 0 39 313 81
Pathology No. of adenomas and CRCs requiring pathology2 1,004 7,161 1,599 1,356 8,909 2,222
CRC work-up and treatment No. receiving PET scan 31 85 6 34 69 8
No. receiving MRI scan 111 307 23 121 247 28
No. receiving CT scan(s) 309 853 64 336 687 78
No. receiving TUS 16 43 3 17 35 4
No. receiving pre-operative radiotherapy3 71 196 15 75 146 17
No. undergoing colorectal resection4 281 779 59 307 635 71
Screening-related health outcomes
Harms5 No. with major bleeding following endoscopy 4 48 7 6 62 10
No. with perforation following endoscopy 2 21 1 2 27 2
No. of deaths from perforation following endoscopy 0 1 0 0 1 0
Screen-detected lesions No. with adenoma(s)6 Total 366 3,320 808 537 4,327 1,128
low-risk 229 2,081 544 333 2,770 740
intermediate/high-risk 137 1,239 264 204 1,558 388
No. with CRC7 Total 309 853 64 336 687 78
stage I 111 308 23 130 303 31
stage II 105 293 22 115 237 26
stage III 69 192 14 68 115 16
stage IV 24 60 4 23 31 5
COL colonoscopy, CRC colorectal cancer, CTC CT colonography, gFOBT guaiac-based faecal occult blood test, FIT faecal immunochemical test, FSIG flexible
sigmoidoscopy, TUS ultrasound; intermediate/high-risk = adenoma(s) ≥10 mm; low-risk = adenoma(s) <10 mm;
1 includes FSIG with and without polypectomy.
2 sum of number of adenomas and colorectal cancers requiring pathology, assuming average of 1.9 adenomas per person; includes screen-detected and
surveillance-detected adenomas.
3 applies to rectal cancer only; includes radiotherapy given with or without chemotherapy.
4 sum of estimates of colon and rectal resections required.
5 includes complications from diagnostic and surveillance endoscopy, including FSIG where relevant.
6 includes individuals with screen-detected and surveillance-detected adenomas.
7 includes individuals with CRC detected at screening and at surveillance.
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of diagnostic colonoscopies required would be around
40% lower; with high uptake (70%) it would be almost
one-third higher. Compared to base-case uptake, with low
uptake 40% fewer cancers would be detected by screening
in year one and 29% fewer in year 10; with high uptake,
32% more cancers would be detected in year one and 14%
more in year 10. Varying specificity had a notable effect
on colonoscopy requirements; for example, for FIT-based
screening, in year one, high specificity (96%) increased the
annual number of diagnostic colonoscopies by 13%, while
low specificity (94%) reduced colonoscopy requirements
by 13%. The impact of varying sensitivity was modest
(1-6% variation around base-case values).
Alternative FIT scenarios
Additional file 3: Table S2 shows the resource require-
ments and health outcomes for the three alternative im-
plementation options for FIT-based screening. Resource
requirements under the age-restricted option (FIT at
55–64 years) were approximately 60% of those required
for screening the full age-range (e.g. 6,437-7,070 diag-
nostic colonoscopies annually vs 11,095-12,414 for the
base-case). Only around half the number of cancers and
adenomas would be detected under this scenario com-
pared to screening the full age-range. Under the medium
roll-out option for the full age-group, resource require-
ments would start low (2,441 diagnostic colonoscopies
in year one vs 11,095 for the base-case scenario) rising
to the same as those for the base-case by year 10. Num-
bers of adenomas and cancers detected followed a simi-
lar pattern. The slow roll-out option generated the
lowest resource requirements in early years, reaching
around 60% of the base-case requirement by year 10, but
only 317 cancers would be detected in year 10 under this
scenario compared to 687 under the base-case.
Relative (secondary) analysis of base-case scenarios
Compared to a policy of no screening, screening by
gFOBT, FIT and FSIG all had potential to reduce deaths
from colorectal cancer in the population within a decade
of implementation. This reduction was evident from the
second year, and was greatest for FIT-based screening
(Figure 2). FIT-based screening at ages 55–74 would re-
sult in 272 colorectal cancer deaths avoided in the popu-
lation in year 10 (26% fewer deaths than under no
screening). In the first five years of screening, all three
scenarios would generate an overall increase in colorectal
cancer cases (Figure 2). After this time, with screening
based on FIT or FSIG, the number of cases would fall
below the number expected with no screening; this fall
would be greatest with FIT (164 cases averted in year 10;
7% reduction compared to no screening).
Discussion
Value of resource modelling
The resource modelling described in this paper could be
viewed as a particular type of budget impact analysis,
with costs expressed in terms of resources and harms ra-
ther than monetary units. As in budget impact analyses
[8], we focussed on the short-term health service impact
of adopting technologies and generated results specific
to the actual target population. Like budget impact ana-
lyses, the types of analyses shown here are intended to
address the practical needs of both decision-makers and
health service planners. They are also intended to com-
plement more conventional cost-effectiveness analyses.
In fact, these analyses did inform decision making in
Ireland: a population-based colorectal cancer screening
programme in 2013 commenced (see below) [51], and
the estimates were used in planning the implementation
of the programme. Our findings suggested that the
(a)                No. of diagnostic colonoscopies required (b)                  No. of screen-detected cancers
Figure 1 Sensitivity analysis: estimated numbers of (a) diagnostic colonoscopies required and (b) screen-detected cancers, for years
1–10, with biennial FITat 55–74 years, as screening uptake varies around base-case value. Numbers at base-case update shown as
diamonds. Numbers under lower and higher update shown as dashes.
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annual endoscopy requirements associated with screen-
ing the 55–74 age-group by biennial FIT would be diffi-
cult, if not impossible, for the health services to meet in
the short-term. However, the magnitude of the health
gains that could be achieved within five years of screen-
ing implementation meant that FIT-based screening
remained the preferred option of policy-makers, despite
the lower resource requirements for gFOBT and FSIG.
Therefore, the policy decision was to introduce biennial
FIT screening; initially the programme will invite individ-
uals aged 60–69 to be screened with the intention of even-
tually rolling-out screening to the full 55–74 age-range.
Delivering sufficient capacity
The few previous analyses of the health service impact of
colorectal cancer screening [12,52,53] all noted that the
ability of the health services to deliver sufficient endoscopy
services was a crucial determinant of programme feasibil-
ity. In England, for example, although screening based on
once-only FSIG was the most cost-effective option [12],
the associated requirements for endoscopy facilities and
staff were considered impossible to meet in the short-term:
instead, a programme based on gFOBT was implemented.
In this study, we found that a programme based on FIT
the option considered most cost-effective [9] – would re-
quire substantially more resources for colonoscopy, CT
colonography, and other diagnostic procedures, than one
based on gFOBT (with FIT as the second-line test in those
who test weakly positive) or FSIG. FIT-based screening
will generate demand for 11,000-15,000 additional colon-
oscopies annually in Ireland. In Ireland, in 2008, 44,000
publically-funded colonoscopies were performed, 2,000 of
these under the National Treatment Purchase Fund. This
fund provides for procedures to be undertaken in private
facilities in the event of long-waiting times in the public
system. In April 2009 more than 2,300 individuals had
been waiting for a colonoscopy for more than three
months [54]. These figures suggest there is little spare
capacity in the service, at least under current working
patterns. They also justify the assumption, inherent in our
analysis, that meeting the demand for “screening-
generated” colonoscopies would require additional cap-
acity over and above existing services.
If not prepared for, increases in colonoscopy demand
can increase waiting times [3]. Studies of screening
programmes for other cancers have found that the
period between having a positive screening test and
waiting for diagnostic follow-up can be a time of consid-
erable anxiety for the individuals concerned (see, for ex-
ample, [55]). Although this issue does not appear to
have been investigated to any great extent for colorectal
screening, it is entirely plausible that many people will
be distressed or anxious in the time between receiving a
positive colorectal screening test result and attending for
colonoscopy. Since anxiety and distress can be consid-
ered a cost of screening, serious consideration should be
given to ensuring that as many people as possible
undergo diagnosis and treatment (if required) as quickly
as possible. Thus, while recent studies continue to build
the clinical case for screening with FIT in preference to
other tests [56-59], the implication of our results is that
any FIT-based programme – in Ireland or elsewhere –
will have to plan carefully how to deliver sufficient ser-
vices for initial diagnosis and ongoing surveillance. The
types of analyses illustrated here, and elsewhere [60],
could usefully inform that planning process.
Strategies that might be used to help address endos-
copy capacity and other resource challenges include
(a)                            Colorectal cancer cases (b)                         Deaths from colorectal cancer
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Figure 2 Relative analysis: estimated difference in numbers of (a) colorectal cancer cases diagnosed, and (b) deaths from colorectal
cancer, in the population with screening versus a policy of no screening, for years 1–10, by screening scenario.
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restricting screening to a narrower age-range, and/or
gradually phasing in screening across the full age-range.
Although restricting FIT-based screening to those aged
55–64 would reduce resource requirements by around
40%, our cost-effectiveness analyses concluded that,
when fully implemented this strategy would be slightly
less desirable than screening the 55–74 age group [9].
This suggests that gradual roll-out across the full age-
range would be preferable, and indeed this is what has
been implemented in Ireland, albeit in a different age-
group initially to that considered here [51]. However, it
is worth remembering that the short-term health gains
achieved with such phased-in screening will be lower
than if the full age-group was screened from the outset.
Safety
Safety is a key consideration in the implementation of
any screening programme [6]. The chances of bowel
perforation and death are, in fact, the major reasons why
some – including the NCSS in Ireland – consider colon-
oscopy unsuitable as a primary screening tool [61]. Col-
onoscopy is, however, the main option for diagnostic
follow-up of those with positive screening tests. Our
analysis suggest that the much higher numbers of colon-
oscopies generated by FIT-based screening than the
other options will result in a higher number of adverse
events. A higher adverse event rate was also evident in
our cost-effectiveness analysis [9]. However, the advan-
tage of the results presented here is that they express the
actual numbers of events that might be expected to
occur in the real-world eligible population: these values
are likely to be more informative for the purposes of
assessing and managing risk.
Screening uptake
A screening test must be acceptable to the population
[6] and one of the main measures of acceptability is
screening uptake. As might be expected, the resource re-
quirements and health gains attainable with screening
were highly dependent on estimates of uptake. For all
screening tests, if actual uptake was higher than our
base-case estimates more cancers would be averted;
however, resource requirements would be higher and
there would be more colonoscopy-related adverse
events. On the other hand, if uptake was lower than the
base-case value, resource requirements would be lower
and there would be fewer adverse events, but there
would also be lower health gains.
Since it is impossible to be entirely certain what up-
take might be attained for any screening test in any
population, base-case values were chosen to be conser-
vative. For the faecal tests, the base-case estimate of
53% was based on the second round of the UK pilot
programmes [34,35]. Although this is lower than
considered desirable by the NCSS in Ireland (60%) [62],
it is higher than in some other European programmes
and pilot programmes [58,63-65]. In Ireland, 51% of al-
most 10,000 Dublin residents invited to complete a FIT
did so [66], suggesting the base-case estimate may be
reasonably realistic. For FSIG, there was no local data to
inform what level of uptake might be realistic. Although
participation rates of 55% and higher have been
achieved in some settings [40,67], generally uptake has
been lower [58,63]. We decided to derive our base-case
value from the large UK Flexible Sigmoidoscopy Trial
[38] to provide some consistency with the source of the
estimates of uptake for the faecal tests.
Since we conducted our analysis evidence has accrued
that uptake may be higher with FIT than gFOBT [68],
although this has not been a universal finding [59]. If
FIT is more acceptable than gFOBT, our estimates of the
resource requirements for FIT relative to gFOBT may be
conservative. However, it is worth noting that the differ-
ence in numbers of screening-related harms may also be
under-estimated.
Limitations
Although parameter values were based on review of the
best available evidence, as with all modelling studies,
some uncertainty remains. Even for gFOBT, which has
been shown to reduce mortality in several trials [69],
performance characteristics remain uncertain. This is
particularly true for newer versions of the test [70]. For
FIT, the available tests have heterogeneous performance
characteristics [70] and for FSIG, information on sensi-
tivity and specificity is limited [18,20,33]. For all tests,
assessment of true sensitivity and specificity is further
complicated by the fact that the reference (gold) stand-
ard, colonoscopy, misses lesions [41]. We addressed this
uncertainty through sensitivity analyses, and found that
varying specificity, in particular, had a notable impact on
requirements for diagnostic investigations. Hence, if the
true test specificity differs from the values used here, the
resource requirements and health outcomes might differ
from those estimated.
We assumed, for gFOBT and FIT, that sensitivity and
specificity remained constant across all screening rounds.
Recent evidence suggests that the ability of gFOBT-based
programmes to identify cancers might decline with re-
peated screenings [71]. The same may be true for FIT. If
so, this would suggest that we may have over-estimated
the health gains associated with screening programmes
based on FIT and gFOBT, although the extent of this
over-estimation is difficult to quantify from currently
available evidence.
We evaluated a strategy that combined gFOBT with
reflex FIT, instead of the more conventional approach of
reflex gFOBT. This was because second-line FIT has
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been shown to limit the number of referrals to colonos-
copy [72,73]. Finding effective strategies to “adjust” screen-
ing when colonoscopy capacity is limited is very topical
[60]. Although gFOBT with reflex FIT is currently not
widely used, our results indicate that it could be an attract-
ive option for delivering population screening in settings
where capacity for diagnostic investigation is expected to
be limited.
We did not estimate resources required for adjuvant
chemotherapy in screen-detected colon cancers, or for
follow-up after resection (which can involve annual col-
onoscopy or CT colonography for five years) since re-
sponsibility for providing these would most likely fall
outwith the screening programme/NCSS. Facilities would,
however, need to be provided elsewhere in the health ser-
vices, so this distinction is somewhat arbitrary.
Conclusions
This study illustrates how resource modelling comple-
ments cost-effectiveness analyses and can help inform
health service decision making and planning. Our results
show that the introduction of FIT-based screening would
quite quickly generate attractive health outcomes – in
terms of reduced numbers of colorectal cancer cases and
deaths – but that it has heavy resource requirements.
These heavy requirements could impact on the feasibility
of any programme based on this screening modality.
Staggered age-based roll-out of FIT-based screening
would allow time to increase endoscopy capacity to meet
requirements. Overall out findings suggest that there are
likely to be many challenges ahead in delivering a high-
quality, safe, and acceptable screening programme to the
population of Ireland.
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